1.1 Processing and Prevention Osteoporosis in Concerning the period after menopause Women
Raloxifene it is designated for processing, and prevention osteoporosis in concerning by the period after menopause women.
1.2 Reduction of Risk of the Aggressive Cancer of a mammary gland in Concerning the period after menopausal Women with Osteoporosis
Raloxifeneit is designated for reduction of risk of an aggressive cancer of a mammary gland in concerning the period after menopause women with  osteoporosis . 
1.3 Reduction of Risk of the Aggressive Cancer of a mammary gland in Concerning the period after menopause Women in High risk
Aggressive Cancer of a mammary gland
EVISTA it is designated for reduction of risk of an aggressive cancer of a mammary gland in concerning the period after menopause women in high
The risk of an aggressive cancer of a mammary gland [sees Clinical Researches (14.4)].
Effect in reduction of level of a cancer of a mammary gland have shown in research concerning the period after menopause
Women in high risk for a cancer of a mammary gland with the 5-year-old planned duration with median continuation of 4.3 years [see
Clinical Researches (14.4)]. Twenty seven percent of participants have received a preparation within 5 years. Long-term effects
And the recommended length of processing is not known.
The high risk of a cancer of a mammary gland is defined as at least one chest biopsy, showing lobular carcinome on a place
(LCIS) or atypical hyperplasia, one or more relatives of the first degree with a mammary gland cancer, or the 5-year-old predicted risk
Mammary gland cancer> 1.66 % (Gejl based on changed model). Among the factors included in changed model of Gejl
The following: current age, number of relatives of the first degree with a mammary gland cancer, number chest biopsy, age
In menarche, nulliparity or age of the first live birth. Workers of public health services can receive Risk Gejl Model
The Estimation tool, typing 1-800-545-5979. Now, no unique clinical opening or result of tests can define quantity of risk
From a mammary gland cancer with confidence.
After an estimation of risk of a developing cancer of a mammary gland, the decision concerning therapy with EVISTA
Should be based on a separate estimation of privileges and risks.
EVISTA does not eliminate risk of a cancer of a mammary gland. Patients should have chest examinations and
mammogramme before to begin EVISTA and should continue regular chest examinations and mammogramme in storage
With good medical practice after beginning processing with EVISTA.
The important Restrictions of Use for Reduction of Risk of the Cancer of a mammary gland
• There is no accessible data concerning effect EVISTA at aggressive level of a cancer of a mammary gland in
Women with the inherited mutations (BRCA1, BRCA2) be able make certain recommendations on

Tags: drug uses, Evista, menopausal problems, osteoporosis, Raloxifene

This entry was posted on Понедельник, Декабрь 14th, 2009 at 8:16 and is filed under Woman Health, Woman health articles. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.